Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control

Parkash Bakhtiani, Owaise Mansuri, Abhijeet Yadav, Chima Osuoha, Patty Knight, Richard Baynosa, Robert Mclafferty, Michael Jakoby

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hyperbaric oxygen (HBO2) therapy is an established intervention for treating chronic diabetic lower extremity ulcers, but the impact of glycemic control on its efficacy has not been determined. The purpose of this study was to evaluate the impact of blood glucose control at initiation of HBO2 treatment on wound healing. Hemoglobin A1c (HbA1c) was measured at start of HBO2 therapy for 22 patients undergoing treatment of chronic lower extremity ulcers at two regional wound care centers. Patients with HbA1c <7.5% were stratified into a "good glycemic control" group (n = 12, mean HbA1c 6.5 ± 0.8%), and patients with HbA1c ≥ 7.5% were stratified into a "poor glycemic control" group (n = 10, mean HbA1c 8.8 ± 1.4%, p = 0.004 compared to "good glycemic control group"). After 20 HBO2 sessions over 30 days in addition to standard wound care interventions, there was no difference in wound healing between the two glycemic control groups as indicated by reduction from baseline in ulcer surface area, depth, or volume. The diabetic lower extremity wound response to HBO2 therapy is unaffected by glycemic control prior to treatment, and HBO2 treatment should not be delayed for suboptimal blood glucose control.

Original languageEnglish (US)
Pages (from-to)183-190
Number of pages8
JournalUndersea and Hyperbaric Medicine
Volume42
Issue number3
StatePublished - 2015
Externally publishedYes

Fingerprint

Ulcer
Oxygen
Hemoglobins
Lower Extremity
Control Groups
Wound Healing
Blood Glucose
Wounds and Injuries
Therapeutics
Hyperbaric Oxygenation

Keywords

  • Diabetic foot ulcer
  • Hyperbaric oxygen
  • Lower extremity ulcer

ASJC Scopus subject areas

  • Physiology (medical)
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Bakhtiani, P., Mansuri, O., Yadav, A., Osuoha, C., Knight, P., Baynosa, R., ... Jakoby, M. (2015). Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control. Undersea and Hyperbaric Medicine, 42(3), 183-190.

Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control. / Bakhtiani, Parkash; Mansuri, Owaise; Yadav, Abhijeet; Osuoha, Chima; Knight, Patty; Baynosa, Richard; Mclafferty, Robert; Jakoby, Michael.

In: Undersea and Hyperbaric Medicine, Vol. 42, No. 3, 2015, p. 183-190.

Research output: Contribution to journalArticle

Bakhtiani, P, Mansuri, O, Yadav, A, Osuoha, C, Knight, P, Baynosa, R, Mclafferty, R & Jakoby, M 2015, 'Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control', Undersea and Hyperbaric Medicine, vol. 42, no. 3, pp. 183-190.
Bakhtiani P, Mansuri O, Yadav A, Osuoha C, Knight P, Baynosa R et al. Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control. Undersea and Hyperbaric Medicine. 2015;42(3):183-190.
Bakhtiani, Parkash ; Mansuri, Owaise ; Yadav, Abhijeet ; Osuoha, Chima ; Knight, Patty ; Baynosa, Richard ; Mclafferty, Robert ; Jakoby, Michael. / Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control. In: Undersea and Hyperbaric Medicine. 2015 ; Vol. 42, No. 3. pp. 183-190.
@article{0f5c3e53339b4b298577f27bc1506ac4,
title = "Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control",
abstract = "Hyperbaric oxygen (HBO2) therapy is an established intervention for treating chronic diabetic lower extremity ulcers, but the impact of glycemic control on its efficacy has not been determined. The purpose of this study was to evaluate the impact of blood glucose control at initiation of HBO2 treatment on wound healing. Hemoglobin A1c (HbA1c) was measured at start of HBO2 therapy for 22 patients undergoing treatment of chronic lower extremity ulcers at two regional wound care centers. Patients with HbA1c <7.5{\%} were stratified into a {"}good glycemic control{"} group (n = 12, mean HbA1c 6.5 ± 0.8{\%}), and patients with HbA1c ≥ 7.5{\%} were stratified into a {"}poor glycemic control{"} group (n = 10, mean HbA1c 8.8 ± 1.4{\%}, p = 0.004 compared to {"}good glycemic control group{"}). After 20 HBO2 sessions over 30 days in addition to standard wound care interventions, there was no difference in wound healing between the two glycemic control groups as indicated by reduction from baseline in ulcer surface area, depth, or volume. The diabetic lower extremity wound response to HBO2 therapy is unaffected by glycemic control prior to treatment, and HBO2 treatment should not be delayed for suboptimal blood glucose control.",
keywords = "Diabetic foot ulcer, Hyperbaric oxygen, Lower extremity ulcer",
author = "Parkash Bakhtiani and Owaise Mansuri and Abhijeet Yadav and Chima Osuoha and Patty Knight and Richard Baynosa and Robert Mclafferty and Michael Jakoby",
year = "2015",
language = "English (US)",
volume = "42",
pages = "183--190",
journal = "Undersea and Hyperbaric Medicine",
issn = "1066-2936",
publisher = "Undersea and Hyperbaric Medical Society",
number = "3",

}

TY - JOUR

T1 - Impact of hyperbaric oxygen on diabetic ulcers is unaffected by glycemic control

AU - Bakhtiani, Parkash

AU - Mansuri, Owaise

AU - Yadav, Abhijeet

AU - Osuoha, Chima

AU - Knight, Patty

AU - Baynosa, Richard

AU - Mclafferty, Robert

AU - Jakoby, Michael

PY - 2015

Y1 - 2015

N2 - Hyperbaric oxygen (HBO2) therapy is an established intervention for treating chronic diabetic lower extremity ulcers, but the impact of glycemic control on its efficacy has not been determined. The purpose of this study was to evaluate the impact of blood glucose control at initiation of HBO2 treatment on wound healing. Hemoglobin A1c (HbA1c) was measured at start of HBO2 therapy for 22 patients undergoing treatment of chronic lower extremity ulcers at two regional wound care centers. Patients with HbA1c <7.5% were stratified into a "good glycemic control" group (n = 12, mean HbA1c 6.5 ± 0.8%), and patients with HbA1c ≥ 7.5% were stratified into a "poor glycemic control" group (n = 10, mean HbA1c 8.8 ± 1.4%, p = 0.004 compared to "good glycemic control group"). After 20 HBO2 sessions over 30 days in addition to standard wound care interventions, there was no difference in wound healing between the two glycemic control groups as indicated by reduction from baseline in ulcer surface area, depth, or volume. The diabetic lower extremity wound response to HBO2 therapy is unaffected by glycemic control prior to treatment, and HBO2 treatment should not be delayed for suboptimal blood glucose control.

AB - Hyperbaric oxygen (HBO2) therapy is an established intervention for treating chronic diabetic lower extremity ulcers, but the impact of glycemic control on its efficacy has not been determined. The purpose of this study was to evaluate the impact of blood glucose control at initiation of HBO2 treatment on wound healing. Hemoglobin A1c (HbA1c) was measured at start of HBO2 therapy for 22 patients undergoing treatment of chronic lower extremity ulcers at two regional wound care centers. Patients with HbA1c <7.5% were stratified into a "good glycemic control" group (n = 12, mean HbA1c 6.5 ± 0.8%), and patients with HbA1c ≥ 7.5% were stratified into a "poor glycemic control" group (n = 10, mean HbA1c 8.8 ± 1.4%, p = 0.004 compared to "good glycemic control group"). After 20 HBO2 sessions over 30 days in addition to standard wound care interventions, there was no difference in wound healing between the two glycemic control groups as indicated by reduction from baseline in ulcer surface area, depth, or volume. The diabetic lower extremity wound response to HBO2 therapy is unaffected by glycemic control prior to treatment, and HBO2 treatment should not be delayed for suboptimal blood glucose control.

KW - Diabetic foot ulcer

KW - Hyperbaric oxygen

KW - Lower extremity ulcer

UR - http://www.scopus.com/inward/record.url?scp=84937512000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937512000&partnerID=8YFLogxK

M3 - Article

C2 - 26152102

AN - SCOPUS:84937512000

VL - 42

SP - 183

EP - 190

JO - Undersea and Hyperbaric Medicine

JF - Undersea and Hyperbaric Medicine

SN - 1066-2936

IS - 3

ER -